CytRx Corporation (CYTR) : During the past 4 weeks, traders have been relatively bearish on CytRx Corporation (CYTR), hence the stock is down -74.53% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -72.53% relative to the S&P 500. The 4-week change in the price of the stock is -73.42% and the stock has fallen -72.12% in the past 1 week. The stock has recorded a 20-day Moving Average of 69.96% and the 50-Day Moving Average is 73.95%.
CytRx Corporation (NASDAQ:CYTR): The stock opened at $0.64 on Friday but the bulls could not build on the opening and the stock topped out at $0.64 for the day. The stock traded down to $0.55 during the day, due to lack of any buying support eventually closed down at $0.63 with a loss of -29.92% for the day. The stock had closed at $0.90 on the previous day. The total traded volume was 17,650,340 shares.
The company Insiders own 12.4% of CytRx Corporation shares according to the proxy statements. Institutional Investors own 28.06% of CytRx Corporation shares.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.